ArticleInternational journal of general medicine2025
Comprehensive Analysis of the Prognostic Significance of ZHX Family Members in Esophageal Carcinoma.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Zinc-finger and homeobox (ZHX) family members have been identified as valuable predictors of survival outcomes in several types of cancers. Nevertheless, the prognostic implications of ZHX factors in esophageal carcinoma (EC) remain unclear. Materials and Methods: Bioinformatic analyses were conducted to evaluate the transcription levels of ZHX factors and their corresponding prognostic significance in EC. Immunohistochemistry was further utilized to assess the association between ZHX3 protein expression and clinicopathologic variables as well as survival outcomes in patient with esophageal squamous cell carcinoma (ESCC). Results: Data from online databases showed no association between ZHX mRNA expression levels and overall survival (OS) in EC patients. However, subgroup analyses revealed significant associations between the expression of ZHX factors and survival outcomes in selected patient cohorts. Immunohistochemical analysis supported that high ZHX3 protein expression was associated with advanced histological grade and unfavorable OS in ESCC patients. Multivariate analysis revealed that ZHX3 expression was an independent prognostic predictor for patient survival. Conclusion: These observations by means of combining bioinformatics and immunohistochemical analyses suggest that ZHX factors is involved in disease progression and may be potential biomarkers for predicting more accurate prognosis for EC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.